[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
about
Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative DisordersN-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line DataReligiosity in patients with Parkinson's disease.Performance of a high-sensitivity dedicated cardiac SPECT scanner for striatal uptake quantification in the brain based on analysis of projection data.Neuroimaging in Parkinson disease: from research setting to clinical practice.Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.[(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites.[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.The relationship between the dopaminergic system and depressive symptoms in cervical dystoniaParkinson's disease as a disconnection syndromeThe effects of ecstasy (MDMA) on brain serotonin transporters are dependent on age-of-first exposure in recreational users and animals.Striatal dopamine D2/3 receptor availability in treatment resistant depressionUsefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's diseasePlasma epidermal growth factor decreased in the early stage of Parkinson's disease.Comparison between Different Intensity Normalization Methods in 123I-Ioflupane Imaging for the Automatic Detection of Parkinsonism.Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects.Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patientsThe dopaminergic system in patients with functional dyspepsia analysed by single photon emission computed tomography (SPECT) and an alpha-methyl-para-tyrosine (AMPT) challenge test.Functional imaging in Parkinson's disease and dementia with Lewy bodies.Visuospatial Attention to Single and Multiple Objects Is Independently Impaired in Parkinson's DiseasePositron emission tomography imaging of transplant function.Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.Dopaminergic modulation of arm swing during gait among Parkinson's disease patients.Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study.AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures.Imaging of serotonin transporters with [123I]FP-CIT SPECT in the human hypothalamus.[(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodiesInvestigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans.Creation and validation of an I-123 FP-CIT template for statistical image analysis using high-resolution SPECT for parkinsonian patients.Patterns of prefrontal dysfunction in alcoholics with and without Korsakoff's syndrome, patients with Parkinson's disease, and patients with rupture and repair of the anterior communicating artery.Imaging analysis of Parkinson's disease patients using SPECT and tractographyThe impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging.SPECT imaging evaluation in movement disorders: far beyond visual assessment.Positive FP-CIT SPECT (DaTSCAN) in Clinical Alzheimer's Disease - An Unexpected Finding?New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications.Implications of nocturnal symptoms towards the early diagnosis of Parkinson's disease.The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI.
P2860
Q26775096-2818AD6A-1C37-4F78-A9FE-4E7033FDEAA8Q30000089-AF7B0EBC-DCF0-4465-B317-E88D2D19F7B2Q30376722-E4C829CA-5C3A-4A6C-8763-1C1FAC8BEE29Q30612253-50B042F5-161F-4C66-A476-98E059197DF7Q30868628-3932A97B-F35C-421D-A0FA-303F3148C091Q31388180-1CA546C0-12B4-40FD-9213-1CE0524000F1Q31911300-FE63EBBF-96BE-492E-8CA8-DE86C41920B4Q32052220-F2F3E4D6-A025-44CB-9DA4-50EB69F368C3Q33841496-D722E71F-1FA7-4A89-B526-508D5C28241FQ33901047-77CD918D-BB9B-43AE-8107-5BA64BACBE35Q34463526-6051DF13-A518-421A-B249-3A9951F72ACAQ34550088-EB832480-4A09-48A2-91CF-A8570FF0F64CQ35454622-DDC70A12-5501-4DD9-A627-A73443175799Q35468295-BCAA618C-6B1C-4F97-B9D5-514EE4E461CAQ35471953-FC911601-5F02-45FF-8AF2-0C2A62BB4835Q35636853-4635AE0C-0B41-4864-819C-A7EB7E29CD5CQ35667024-A42EDEC5-EF84-48D6-B51F-1626346FDFB4Q35692709-F3634540-7C02-4753-90E5-E125D35B8A3AQ35781879-2F6FA626-BAF1-4E06-9C70-08192D26B6CAQ35861384-CD0DBA95-F2E7-4DF1-A611-29830043F272Q35863417-FA2FCAF5-68FE-48C9-BF62-36913C25BEADQ35952366-5F5ABBEC-0ED8-48B8-B979-91D53A267DC3Q36045402-B8B46287-6D5D-48D3-9BC1-68BBEEDA8CF9Q36154790-D2517C89-7AE1-4E45-8A37-1E2047528ECFQ36173465-46D948E6-1935-4E71-842D-7980336209F3Q36318603-EFBDE94F-03F7-4451-8B8D-4BD04C61D13FQ36738260-9AAC6446-4438-47D4-9CBA-0CB86E55B530Q36738339-18AEA243-AD9A-4856-9139-2E9C3A8DD6FEQ36827950-B62C8055-8828-4AF4-8F4E-96F6C8CDF3FAQ36834554-939ECEE1-043C-465A-AF5E-24687F08736DQ37106123-2DCE3C10-3DB8-4ACF-92DB-F59E08E0D158Q37127709-30EFBB27-CE68-48D7-8EAE-357FCED9D966Q37165733-1CB5724C-5C56-4B4E-8A01-0556D7487CC9Q37454387-55881870-6CB4-491C-BEEA-FECC03AC1E93Q37605294-38DC1CCD-9225-48C6-AACC-341B6F63C80CQ37815026-8171BAAF-B410-4482-8D28-589CEB68CA5FQ38006466-E3405B96-F1C9-4251-9DF4-AD68A71177B5Q38067141-79C21FD2-1605-4DA6-A78C-9D6B7C84E8B0Q38185511-C9AD2E42-04C1-4472-8A10-390C595388FAQ38217493-6D7B68A4-7F2E-4918-9DFA-9179FE57629C
P2860
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
[123I]FP-CIT SPECT shows a pro ...... advanced Parkinson's disease.
@en
type
label
[123I]FP-CIT SPECT shows a pro ...... advanced Parkinson's disease.
@en
prefLabel
[123I]FP-CIT SPECT shows a pro ...... advanced Parkinson's disease.
@en
P2860
P50
P356
P1476
[123I]FP-CIT SPECT shows a pro ...... advanced Parkinson's disease.
@en
P2860
P304
P356
10.1136/JNNP.62.2.133
P4011
504a9a632378eb20e074a274552963958cc7ce1f
P407
P577
1997-02-01T00:00:00Z